Search results
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts
Here's Why Investors Should Avoid Air Lease Stock for Now
Air Lease AL is mired in significant challenges stemming from increased expenses and weak liquidity. Geopolitical uncertainty is also hurting the company’s prospects, making it an unattractive
Alcoa's Aluminum Segment Gains Momentum: Can it Sustain?
Alcoa Corporation’s AA Aluminum segment is benefiting from strong demand in the electrical and packaging end markets in North America and Europe and continued progress on the San Ciprián, Spain
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, Mounjaro and Zepbound, Lilly has become the first and only drugmaker to hit a
Qualcomm Witnesses Just 8.2% Growth in Past Year: Reason to Worry?
Qualcomm Incorporated QCOM shares have gained a modest 8.2% over the past year compared with the industry’s growth of 35.7%. Although it has outperformed peers like Hewlett Packard Enterprise
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Shares of Ironwood Pharmaceuticals IRWD were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it
Lumentum Trades Near 52-Week High: Is the LITE Stock Still a Buy?
Lumentum Holdings LITE shares closed at $386.11 on Friday, which is close to the 52-week high of $401.60 it hit on Dec. 24, 2025. LITE shares have jumped a whopping 326.9% in a year, outperforming
3 Reasons Why Growth Investors Shouldn't Overlook REV Group (REVG)
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't
3 Reasons Growth Investors Will Love Vertiv (VRT)
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to
Here is Why Growth Investors Should Buy FMC Technologies (FTI) Now
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to
Is APi (APG) a Solid Growth Stock? 3 Reasons to Think "Yes"
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to
Is Argan (AGX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to
Vertiv Rallies 31% in a Year: Should You Buy the Stock?
Vertiv VRT shares have gained 31% in the trailing 12-month period, outperforming the broader Zacks Computer and Technology sector’s increase of 22.6%. The Zacks Computers - IT Services industry
Hennes & Mauritz (HNNMY) Upgraded to Buy: What Does It Mean for the Stock?
Hennes & Mauritz AB (HNNMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Kezar Life Sciences, Inc. (KZR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates
S&P Global (SPGI) Upgraded to Buy: Here's Why
S&P Global (SPGI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Vivos Therapeutics, Inc. (VVOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces
MP Materials Trades at Premium Value: Here's How to Play the Stock
MP Materials MP is trading at a forward 12-month price/sales multiple of 22.93X, a significant premium to the industry’s 1.44X. It has a Value Score of F, which suggests that the stock appears




